Adlai Nortye Group (ANL) vs Corvus Pharmaceuticals (CRVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Corvus Pharmaceuticals (CRVS) over the past year, gaining 796.5% versus a gain of 51.5%. Adlai Nortye Group is the larger company by market cap ($998.8 million vs $858.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | CRVS |
|---|---|---|
| Share price | $15.51 | $10.21 |
| Market cap | $998.81M | $858.87M |
| 1-day change | +10.39% | -1.92% |
| YTD return | +992.25% | +35.19% |
| 1-year return | +796.53% | +51.53% |
| 5-year return | — | +110.30% |
| EPS (TTM) | $-0.66 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $26.95 |
| 52-week low | $0.879 | $6.39 |
| Distance from 52-week high | -10.09% | -62.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.20% | +224.58% |
| Average volume | 175.26K | 986.04K |
| Shares outstanding | 58.73M | 84.12M |
| Employees | 109 | 37 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed CRVS by 745.0 percentage points over the past year.
- The two companies sit in different sectors: Adlai Nortye Group in Healthcare and Corvus Pharmaceuticals in Health Care.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
ANL vs CRVS FAQ
Which is bigger, Adlai Nortye Group or Corvus Pharmaceuticals?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $998.81M compared with $858.87M for Corvus Pharmaceuticals (CRVS).
Which stock has performed better over the past year, ANL or CRVS?
ANL returned +796.53% over the past 12 months, compared with +51.53% for CRVS (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Corvus Pharmaceuticals in the same industry?
No. Adlai Nortye Group is in the Healthcare sector, while Corvus Pharmaceuticals is in Health Care.